Syndax Pharmaceuticals, Inc. (SNDX) Financial Statements (2023 and Earlier)

Company Profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments439,936 59,77580,911129,974105,330
Cash and cash equivalents221,965 24,60933,76935,16823,844
Short-term investments217,971 35,16647,14294,80681,486
Restricted cash and investments   101106151
Receivables429 116253377306
Prepaid expense1,022 727621670831
Deposits current assets6,894 1,2976631,2861,630
Other undisclosed current assets115 4167971,029262
Total current assets:448,396 62,33183,346133,442108,510
Noncurrent Assets
Operating lease, right-of-use asset983 716
Property, plant and equipment278 281373267260
Long-term investments and receivables    3,246 
Long-term investments    3,246 
Other noncurrent assets  197219231243
Total noncurrent assets:1,261 1,1945923,744503
TOTAL ASSETS:449,657 63,52583,938137,186109,013
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,375 9,6474,8625,0484,653
Accounts payable5,669 6,1781,4392,2322,375
Accrued liabilities2,364 669619423637
Employee-related liabilities4,342 2,8002,8042,3931,641
Deferred revenue  1,517
Debt  478   
Derivative instruments and hedges, liabilities187     
Deferred revenue and credits1,5731,220
Contract with customer, liability1,517
Other undisclosed current liabilities8,121 6,7269,7269,1774,493
Total current liabilities:20,683 18,36816,10515,79810,366
Noncurrent Liabilities
Long-term debt and lease obligation20,606 419   
Long-term debt, excluding current maturities19,895     
Operating lease, liability711 419
Liabilities, other than long-term debt  13,13814,78617,06914,508
Deferred revenue and credits16,75914,220
Deferred revenue  13,133
Contract with customer, liability14,650
Other liabilities  5136310288
Other undisclosed noncurrent liabilities(711)     
Total noncurrent liabilities:20,606 13,55714,78617,06914,508
Total liabilities:41,289 31,92530,89132,86724,874
Stockholders' equity
Stockholders' equity attributable to parent408,368 31,60053,047104,31984,139
Common stock6 3222
Additional paid in capital952,019 527,067492,493470,571389,374
Accumulated other comprehensive income (loss)45  (25)(143)56
Accumulated deficit(543,702) (495,470)(439,423)(366,111)(305,293)
Total stockholders' equity:408,368 31,60053,047104,31984,139
TOTAL LIABILITIES AND EQUITY:449,657 63,52583,938137,186109,013

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues139,709 1,5171,5172,1081,220
Revenue, net2,1081,220
Gross profit:139,709 1,5171,5172,1081,220
Operating expenses(113,489) (59,056)(77,393)(64,062)(44,986)
Operating income (loss):26,220 (57,539)(75,876)(61,954)(43,766)
Nonoperating income (expense)(1,294) 1,4921,9151,152(706)
Investment income, nonoperating403     
Other nonoperating income (expense)202 (79)(27)(269)41
Interest and debt expense(1,899)     
Income (loss) before gain (loss) on sale of properties:23,027 (56,047)(73,961)(60,802)(44,472)
Other undisclosed net income1,899     
Net income (loss) attributable to parent:24,926 (56,047)(73,961)(60,802)(44,472)
Preferred stock dividends and other adjustments     (2,598)
Net income (loss) available to common stockholders, diluted:24,926 (56,047)(73,961)(60,802)(47,070)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):24,926 (56,047)(73,961)(60,802)(44,472)
Comprehensive income (loss):24,926 (56,047)(73,961)(60,802)(44,472)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent49 25118(199)28
Comprehensive income (loss), net of tax, attributable to parent:24,975 (56,022)(73,843)(61,001)(44,444)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: